Deriving a dose and regimen for anti-glucosaminidase antibody passive-immunisation for patients with Staphylococcus aureus osteomyelitis
作者: C C LeeC JiaoE GerszJ R OwenS L KatesC A BeckC XieJ L DaissV PostT F MoriartyS ZeiterE M SchwarzG Muthukrishnan
作者单位: 1Centre for Musculoskeletal Research, University of Rochester Medical Centre, Rochester, NY, USA.Edward_schwarz at
刊名: Eur Cell Mater, 2020, Vol.39 , pp.96-107
来源数据库: European Cells and Materials (eCM)
DOI: 10.22203/eCM.v039a06
原始语种摘要: Staphylococcus aureus (S. aureus) osteomyelitis remains a major clinical problem. Anti-glucosaminidase (Gmd) antibodies (1C11) are efficacious in prophylactic and therapeutic murine models. Feasibility, safety and pharmacokinetics of 1C11 passive immunisation in sheep and endogenous anti-Gmd levels were quantified in osteomyelitis patients.3 sheep received a 500 mg intravenous (i.v.) bolus of 1C11 and its levels in sera were determined by enzyme-linked immunosorbent assay (ELISA) over 52 d. A humanised anti-Gmd monoclonal antibody, made by grafting the antigen-binding fragment (Fab) portion of 1C11 onto the fragment crystallisable region (Fc) of human IgG1, was used to make a standard curve of mean fluorescent intensity versus concentration of anti-Gmd. Anti-Gmd serum levels were...
全文获取路径: European Cells and Materials (eCM) 
影响因子:4.558 (2012)

  • osteomyelitis 骨髓炎
  • immunisation 防染处理
  • antibody 抗体
  • endogenous 内成的
  • sheep 
  • prophylactic 预防性的
  • concentration 浓度
  • monoclonal 单细胞系的
  • immunosorbent 免疫吸收剂
  • grafting 嫁接